



Genocea Biosciences  
Investor Relations Department  
100 Acom Park Drive, 5th Floor  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: GNCA


Last Trade:	1.15
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.02 ↓ (-1.709%)
Day Range	1.14 - 1.21
52-Week Range	1.03 - 7.29
Volume	375,365

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Nov 8, 2017 [Genocea to Present at Stifel 2017 Healthcare Conference](#)
- Nov 7, 2017 [Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017](#)
- Nov 2, 2017 [Genocea Reports Third Quarter 2017 Financial Results](#)
- Oct 26, 2017 [Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET](#)
- Sep 25, 2017 [Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines](#)

### Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 17, 2017 [Annual Report \(10-K\)](#)
- Apr 21, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 9, 2017 [Quarterly Report \(10-Q\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)